Elisabeth Wassner Fritsch

CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.

Shaji Kumar, Carlos Bachier, Michèle Cavo et al. · Journal of Clinical Oncology · 2023 · 40 citations

Life Sciences, Immunology, Pharmacology +7

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Hearn Jay Cho, Luciano J. Costa, Faith E. Davies et al. · Blood · 2018 · 21 citations

Medicine, Oncology, Pharmacotherapy +14

GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

Laurie H. Sehn, Neil Chua, Greg Dueck et al. · Journal of Clinical Oncology · 2015 · 20 citations

Medicine, Pharmacology, Pharmacotherapy +13